The first participant has been dosed in a Phase 1 clinical trial testing TNV262, an experimental therapy that Tenvie Therapeutics is developing as a potential treatment for multiple sclerosis (MS) and other conditions including obesity and cardiovascular disease. The Phase 1a/1b study will test single and multiple doses of TNV262 in healthy volunteers and people […]
The post Dosing begins in trial testing treatment for MS, obesity appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com